Histo-Molecular Factors of Response to Combined Chemotherapy and Immunotherapy in Non-Small Cell Lung Cancers
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Histo-Molecular Factors of Response to Combined Chemotherapy and Immunotherapy in Non-Small Cell Lung Cancers
Authors
Keywords
-
Journal
Targeted Oncology
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2023-11-03
DOI
10.1007/s11523-023-01009-w
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
- (2023) L.E. Hendriks et al. ANNALS OF ONCOLOGY
- Atezolizumab with or without bevacizumab and platinum-pemetrexed in patients with stage IIIB/IV non-squamous non-small cell lung cancer with EGFR mutation, ALK rearrangement or ROS1 fusion progressing after targeted therapies: a multicenter phase II open-label non-randomized study GFPC 06-2018
- (2023) Olivier Bylicki et al. EUROPEAN JOURNAL OF CANCER
- Sintilimab plus chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer with disease progression after EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): second interim analysis from a double-blind, randomised, placebo-controlled, phase 3 trial
- (2023) Shun Lu et al. Lancet Respiratory Medicine
- Immunotherapy in Elderly Patients Affected by Non-Small Cell Lung Cancer: A Narrative Review
- (2023) Michele Montrone et al. Journal of Clinical Medicine
- Pemetrexed and platinum with or without pembrolizumab for tyrosine kinase inhibitor (TKI)-resistant, EGFR-mutant, metastatic nonsquamous NSCLC: Phase 3 KEYNOTE-789 study.
- (2023) James Chih-Hsin Yang et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in KRAS-mutated non-small cell lung cancer with STK11, KEAP1, or TP53 comutations: subgroup results from the phase III IMpower150 trial
- (2022) Howard Jack West et al. Journal for ImmunoTherapy of Cancer
- Biomarkers of response to PD-1 pathway blockade
- (2022) Hanxiao Li et al. BRITISH JOURNAL OF CANCER
- HER2-Altered Non-Small Cell Lung Cancer: Biology, Clinicopathologic Features, and Emerging Therapies
- (2022) Xin Yu et al. Frontiers in Oncology
- Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non–Small-Cell Lung Cancer
- (2021) Hossein Borghaei et al. JOURNAL OF CLINICAL ONCOLOGY
- Anti-PD-(L)1 for KRAS-mutant advanced non-small–cell lung cancers: a meta-analysis of randomized–controlled trials
- (2021) Thierry Landre et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Brief Report: Efficacy of immune checkpoint inhibitors alone or in combination with chemotherapy in NSCLC harboring ERBB2 mutations
- (2021) Felix C. Saalfeld et al. Journal of Thoracic Oncology
- Comparison of the outcome between immunotherapy alone or in combination with chemotherapy in EGFR-mutant non-small cell lung cancer
- (2021) Chia-I Shen et al. Scientific Reports
- Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer
- (2021) Marcelo V Negrao et al. Journal for ImmunoTherapy of Cancer
- Durable Response to the Combination of Atezolizumab With Platinum-Based Chemotherapy in an Untreated Non-Smoking Lung Adenocarcinoma Patient With BRAF V600E Mutation: A Case Report
- (2021) Xiaomin Niu et al. Frontiers in Oncology
- A Randomized Phase II Study Comparing Nivolumab with Carboplatin–Pemetrexed for EGFR-Mutated NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors (WJOG8515L)
- (2021) Hidetoshi Hayashi et al. CLINICAL CANCER RESEARCH
- STK11/LKB1 and KEAP1 mutations in non-small cell lung cancer: Prognostic rather than predictive?
- (2021) Alessandro Di Federico et al. EUROPEAN JOURNAL OF CANCER
- Clinical impact of pembrolizumab combined with chemotherapy in elderly patients with advanced non-small-cell lung cancer
- (2021) Kenji Morimoto et al. LUNG CANCER
- 363 KEYNOTE-042 5-year survival update: pembrolizumab versus chemotherapy in patients with previously untreated, PD-L1–positive, locally advanced or metastatic non–small-cell lung cancer
- (2021) Gilberto de Castro et al. Journal for ImmunoTherapy of Cancer
- Immunotherapy in Non-Small Cell Lung Cancer With Actionable Mutations Other Than EGFR
- (2021) Karan Seegobin et al. Frontiers in Oncology
- Elucidation of the relationships of MET protein expression and gene copy number status with PD-L1 expression and the immune microenvironment in non-small cell lung cancer
- (2020) Katsuhiro Yoshimura et al. LUNG CANCER
- The Emerging Role of the c-MET-HGF Axis in Non-small Lung Cancer Tumor Immunology and Immunotherapy
- (2020) Helen F. Titmarsh et al. Frontiers in Oncology
- PD-(L)1 Inhibitors in Combination with Chemotherapy as First-Line Treatment for Non-Small-Cell Lung Cancer: A Pairwise Meta-Analysis
- (2020) Jorge García-González et al. Journal of Clinical Medicine
- Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors
- (2020) Rilan Bai et al. Biomarker Research
- MET Amplification (MET/CEP7 Ratio ≥ 1.8) Is an Independent Poor Prognostic Marker in Patients With Treatment-naive Non–Small-cell Lung Cancer
- (2020) Wei Yin et al. Clinical Lung Cancer
- Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial
- (2019) Martin Reck et al. Lancet Respiratory Medicine
- Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry
- (2019) J Mazières et al. ANNALS OF ONCOLOGY
- Association of TP53 mutations with response and longer survival under immune checkpoint inhibitors in advanced non-small-cell lung cancer
- (2019) Sandra Assoun et al. LUNG CANCER
- LBA5 KRAS mutational status and efficacy in KEYNOTE-189: Pembrolizumab (pembro) plus chemotherapy (chemo) vs placebo plus chemo as first-line therapy for metastatic non-squamous NSCLC
- (2019) S Gadgeel et al. ANNALS OF ONCOLOGY
- The superior efficacy of anti-PD-1/PD-L1 immunotherapy in KRAS-mutant non-small cell lung cancer that correlates with an inflammatory phenotype and increased immunogenicity
- (2019) Chengming Liu et al. CANCER LETTERS
- MET-oncogenic and JAK2-inactivating alterations are independent factors that affect regulation of PD-L1 expression in lung cancer
- (2018) Maria Saigi et al. CLINICAL CANCER RESEARCH
- A Phase II Study of Pembrolizumab in EGFR-mutant, PD-L1+, Tyrosine Kinase Inhibitor (TKI) Naïve Patients with Advanced NSCLC
- (2018) A. Lisberg et al. Journal of Thoracic Oncology
- Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer
- (2018) Leena Gandhi et al. NEW ENGLAND JOURNAL OF MEDICINE
- STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS -Mutant Lung Adenocarcinoma
- (2018) Ferdinandos Skoulidis et al. Cancer Discovery
- Optimization of routine testing for MET exon 14 splice site mutations in non-small cell lung cancer patients
- (2018) Clotilde Descarpentries et al. Journal of Thoracic Oncology
- Results From the Phase III Randomized Trial of Onartuzumab Plus Erlotinib Versus Erlotinib in Previously Treated Stage IIIB or IV Non–Small-Cell Lung Cancer: METLung
- (2017) David R. Spigel et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeting MET in Lung Cancer: Will Expectations Finally Be MET?
- (2017) Alexander Drilon et al. Journal of Thoracic Oncology
- Checkpoint Inhibitors in Metastatic EGFR- Mutated Non–Small Cell Lung Cancer—A Meta-Analysis
- (2017) Chee Khoon Lee et al. Journal of Thoracic Oncology
- Prognostic value of KRAS mutation in advanced non-small-cell lung cancer treated with immune checkpoint inhibitors: A meta-analysis and review
- (2017) Jung Han Kim et al. Oncotarget
- EGFR mutation correlates with uninflamed phenotype and weak immunogenicity, causing impaired response to PD-1 blockade in non-small cell lung cancer
- (2017) Zhong-Yi Dong et al. OncoImmunology
- Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma
- (2016) Zhong-Yi Dong et al. CLINICAL CANCER RESEARCH
- EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis
- (2016) J. F. Gainor et al. CLINICAL CANCER RESEARCH
- Clinicopathological significance and concordance analysis of c-MET immunohistochemistry in non-small cell lung cancers: A meta-analysis
- (2016) Jung-Soo Pyo et al. PATHOLOGY RESEARCH AND PRACTICE
- Improved diagnostics targeting c-MET in non-small cell lung cancer: expression, amplification and activation?
- (2015) I. Watermann et al. Diagnostic Pathology
- Clinical Validation of Targeted Next Generation Sequencing for Colon and Lung Cancers
- (2015) Nicky D’Haene et al. PLoS One
- Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer
- (2013) L Bracci et al. CELL DEATH AND DIFFERENTIATION
- Randomized Phase II Trial of Onartuzumab in Combination With Erlotinib in Patients With Advanced Non–Small-Cell Lung Cancer
- (2013) David R. Spigel et al. JOURNAL OF CLINICAL ONCOLOGY
- Favorable clinical outcomes of pemetrexed treatment in anaplastic lymphoma kinase positive non-small-cell lung cancer
- (2012) Ha Yeon Lee et al. LUNG CANCER
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search